AbstractMost patients with recurrent ovarian cancer (ROC) undergo a series of remissions and recurrences, therefore the additive or cumulative toxicity of chemotherapy must be factored into their treatment plan. There are challenges in defining tailored therapeutic approaches, including optimal timing and drug sequencing management strategies to treat patients with ROC. This is particularly relevant as new cytotoxic drugs and biological agents become available. Many of these drugs are associated with increased toxicity and with no observable survival advantage. Therefore current treatment options for the heavily-pretreated relapsing OC patient population are frequently guided by safety considerations and convenience. Rechallenge with platin...
AbstractA platinum-taxane doublet has been established as the standard of care in the initial chemot...
The goal of recurrent ovarian cancer (ROC) treatment is no longer just palliation, but prolonging su...
Dose-dense administration of paclitaxel as well as intraperitoneal administration of platinum and pa...
AbstractMost patients with recurrent ovarian cancer (ROC) undergo a series of remissions and recurre...
The majority of patients with advanced ovarian cancer need a second-line treatment for recurrent dis...
AbstractOvarian cancer is the 5th most common cancer found in women in the UK. It is the leading cau...
Ovarian cancer is the 5th most common cancer found in women in the UK. It is the leading cause of de...
Substantial progress has been made since the early 1990s regarding the treatment of patients with ov...
AbstractBackgroundThe optimal therapy to treat relapsed, platinum-sensitive ovarian cancer remains e...
Ovarian cancer (OC) is the fifth most common cause of cancer death in women. Although significant pr...
AbstractOvarian cancer (OC) is the leading cause of death from gynecological malignancies. In spite ...
Fifty-seven patients who had progressed during or relapsed after randomized first-line combination c...
We conducted a phase I-II study with escalating paclitaxel doses plus carboplatin at a fixed dose fo...
INTRODUCTION: Optimal management of recurrent ovarian cancer (ROC) remains an area of uncertainty. A...
Fifty-seven patients who had progressed during or relapsed after randomized first-line combination c...
AbstractA platinum-taxane doublet has been established as the standard of care in the initial chemot...
The goal of recurrent ovarian cancer (ROC) treatment is no longer just palliation, but prolonging su...
Dose-dense administration of paclitaxel as well as intraperitoneal administration of platinum and pa...
AbstractMost patients with recurrent ovarian cancer (ROC) undergo a series of remissions and recurre...
The majority of patients with advanced ovarian cancer need a second-line treatment for recurrent dis...
AbstractOvarian cancer is the 5th most common cancer found in women in the UK. It is the leading cau...
Ovarian cancer is the 5th most common cancer found in women in the UK. It is the leading cause of de...
Substantial progress has been made since the early 1990s regarding the treatment of patients with ov...
AbstractBackgroundThe optimal therapy to treat relapsed, platinum-sensitive ovarian cancer remains e...
Ovarian cancer (OC) is the fifth most common cause of cancer death in women. Although significant pr...
AbstractOvarian cancer (OC) is the leading cause of death from gynecological malignancies. In spite ...
Fifty-seven patients who had progressed during or relapsed after randomized first-line combination c...
We conducted a phase I-II study with escalating paclitaxel doses plus carboplatin at a fixed dose fo...
INTRODUCTION: Optimal management of recurrent ovarian cancer (ROC) remains an area of uncertainty. A...
Fifty-seven patients who had progressed during or relapsed after randomized first-line combination c...
AbstractA platinum-taxane doublet has been established as the standard of care in the initial chemot...
The goal of recurrent ovarian cancer (ROC) treatment is no longer just palliation, but prolonging su...
Dose-dense administration of paclitaxel as well as intraperitoneal administration of platinum and pa...